StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Mitoxantrone

HCID 4212
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
65271-80-9
Standard-SMILES
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
InChIKey
KKZJGLLVHKMTCM-UHFFFAOYSA-N
Summenformel
C22H28N4O6
Durchschnittliche Molmasse
444,5 g/mol
Monoisotopische Masse
444,20088462

Überblick

Mitoxantrone is a dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8. It has a role as an analgesic and an antineoplastic agent.

Namen und Bezeichner

Bevorzugter Name
Mitoxantrone
IUPAC
1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
Englischer Name
Mitoxantrone
Summenformel
C22H28N4O6
Molmasse
444.48

Namen und Synonyme

mitoxantrone65271-80-9MitozantroneMitoxanthroneDHAQMitoxantronMitoxantronaMitoxantronumMisostolNSC-279836NSC 279836BZ114NVM5P
Weitere Namen anzeigen
itoxantronedihydroxyanthraquinoneNSC-27983MitoxantroneBasePharmasubstanceEP4
NSC2798361,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedioneDTXSID40469471,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONECHEBI:50729L01DB07Ralenova

Datenbank-Bezeichner

CAS
65271-80-9
PubChem CID
4212
DTXSID
DTXSID4046947
ChEMBL
CHEMBL58
ChEBI
CHEBI:50729
UNII
BZ114NVM5P
EC Number
833-758-3
Nikkaji
J19.969I、J710.751J

Eigenschaften

Berechnete Struktureigenschaften

XLogP
1
Polarare Oberfläche (TPSA)
163 Ų
H-Brücken-Donoren
8
H-Brücken-Akzeptoren
10
Frei drehbare Bindungen
12
Schwere Atome
32
Formalladung
0
Komplexität
571

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

LogP · 2 Einträge

-3.1

0.07

Solubility7.34e-01 g/L
Human DrugsBreast Feeding; Lactation; Milk, Human; Antineoplastic Agents
Physical DescriptionLiquid
Collision Cross Section198.57 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
170 · 170-1740C
Siedepunkt
554.47 °C · 554.47°C (rough estimate)
Dichte
1.3049 · 1.3049 (rough estimate)
Brechungsindex
1.65 · 1.6500 (estimate)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H351 (100%): Suspected of causing cancer [Warning Carcinogenicity]

P203, P273, P280, P318, P391, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Gefahrenhinweise

Regulatory InformationHazard Traits - Carcinogenicity
Hazard Classes and CategoriesCarc. 2 (100%)

Toxikologische Informationen

Health EffectsCardiomyopathy is a particularly concerning effect as it is irreversible. [Wikipedia]
Hepatotoxicity · 1 Eintrag

Chemotherapy with mitoxantrone alone is associated with serum enzyme elevations in up to 40% of patients, but these elevations are generally mild-to-moderate in severity, transient and not accompanied by symptoms or jaundice. Higher rates of liver enzyme elevations have been reported with combination chemotherapeutic regimens that include mitoxantrone. In high doses, mitoxantrone has been associated with a high rate of jaundice, but the degree of hyperbilirubinemia has been mild, transient and not associated with significant serum enzyme elevations or evidence of hepatitis. Rare instances of acute liver injury have been reported in patients taking mitoxantrone, including a single case of drug-rash with eosinophilia and systemic symptoms (DRESS). The latency to onset was 8 weeks and the pattern of serum enzyme elevations was cholestatic and later mixed. Immunoallergic features were prominent and appeared to respond to corticosteroid therapy. Other drugs were being taken and the association with mitoxantrone was not definite (Case 1). Thus, idiosyncratic and clinically apparent liver injury from mitoxantrone may occur but is quite rare.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

L01DB07

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein Binding78%
PharmacodynamicsMitoxantrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.
Mechanism of Action · 1 Eintrag

Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.

Biological Half-Life75 hours
Metabolism/Metabolites · 2 Einträge

Hepatic

Hepatic Half Life: 75 hours

FDA Pharmacological Classification · 6 Einträge

BZ114NVM5P

MITOXANTRONE

Established Pharmacologic Class [EPC] - Topoisomerase Inhibitor

Mechanisms of Action [MoA] - Topoisomerase Inhibitors

Mitoxantrone is a Topoisomerase Inhibitor. The mechanism of action of mitoxantrone is as a Topoisomerase Inhibitor.

MITOXANTRONE

MeSH Pharmacological Classification · 3 Einträge

Compounds capable of relieving pain without the loss of CONSCIOUSNESS.

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.

Zugehörige Reaktionen

22
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 65397
HRID 65397als Edukt
Reaktionsgleichung von HRID 65398
HRID 65398als Edukt
Reaktionsgleichung von HRID 370432
HRID 370432als Produkt
Reaktionsgleichung von HRID 370573
HRID 370573als Edukt
Reaktionsgleichung von HRID 370574
HRID 370574als Edukt
Reaktionsgleichung von HRID 477419
HRID 477419als Produkt
Reaktionsgleichung von HRID 620290
HRID 620290als Edukt
Reaktionsgleichung von HRID 647783
HRID 647783als Edukt
ZurückSeite 1 von 3

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
storage temp.
2 · Keep in dark place,Sealed in dry,2-8°C
Löslichkeit
DMSO (Slightly), Methanol (Sparingly), Water (Slightly)
pka
5.99 · pKa 5.99 (Uncertain);8.13 (Uncertain)
Aggregatzustand
Solid
Farbe
Dark Blue to Black
InChI
InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
InChIKey
KKZJGLLVHKMTCM-UHFFFAOYSA-N
SMILES
C1(O)=C2C(C(=O)C3=C(C2=O)C(NCCNCCO)=CC=C3NCCNCCO)=C(O)C=C1
CAS Datenbank
65271 · 65271-80-9(CAS DataBase Reference)
Exposure RoutesIntravenous injection. Poorly absorbed following oral administration.
Toxicity Summary · 1 Eintrag

Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.

Signs and SymptomsSevere leukopenia with infection.
Carcinogen Classification · 6 Einträge

Mitoxantrone

Group 2B: Possibly carcinogenic to humans

Volume 76: (2000) Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents

2000

1999

2B, possibly carcinogenic to humans. (L135)

Drug Induced Liver Injury · 5 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

mitoxantrone

DILI Positive

Intravenous

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
3
hs_code
2922.50.2500
RTECS-Nr.
CB5748500
risk_code
46-61-26/27/28
hazard_code
T,T+
safety_code
53-36/37/39-45-22
Absorption, Distribution and Excretion · 3 Einträge

Poorly absorbed following oral administration

1000 L/m2

21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2]

Cellular LocationsCytoplasm

Verwendung und Herstellung

Uses · 2 Einträge

Use (kg) in USA (2002): 1

For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis. Mitoxantrone is an Anthracenedione (not an anthracycline) antineoplastic agent.

Anwendungen

VerwendenMitoxantrone is a DNA intercalating drug. Mitoxantrone inhibits DNA synthesis. Mitoxantrone is used as an anti-cancer agent.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Dihydro-1,4,5,8-tetrahydroxyanthraquinone2-(2-Aminoethylamino)ethanolTetrachlor-p-benzochinonN,N,N',N'-Tetramethylethylendiamin2,3-Dihydro-1,4,5,8-tetrahydroxyanthrachinon